title: The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?
authors.forename: Robert A
authors.initials: RA
authors.lastname: Cohen
authors.forename: Robert S
authors.initials: RS
authors.lastname: Brown
mesh_terms: D002908:Chronic Disease; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects*; D006333:Heart Failure / Q000453:epidemiology; D006397:Hematinics / Q000009:adverse effects; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy*; D010353:Patient Education as Topic / Q000379:methods*; D010817:Physician-Patient Relations; D011994:Recombinant Proteins / Q000009:adverse effects; D006435:Renal Dialysis; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012308:Risk Management; D020521:Stroke / Q000453:epidemiology; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa